Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (3) : 271-276     DOI: 10.1007/s11684-009-0054-1
Research articles |
Correlation between viral load and liver cirrhosis in chronic hepatitis B patients
Lili LIU MM , Jiyao WANG MD , Weimin SHE MM ,
Department of Gastroenterology and Hepatology, Zhong Shan Hospital, Fudan University, Shanghai 200032, China;
Download: PDF(108 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  The aim of this paper is to investigate the relationship between hepatitis B virus (HBV) DNA levels during the course and the progression to cirrhosis with chronic hepatitis B. A total of 239 chronic hepatitis B patients confirmed by liver biopsy between 2001 and 2007 were followed up for a median of 28 months. Compared with the patients without cirrhosis, the patients progressed to cirrhosis were older and with higher HBV-DNA levels at end point. However, there was no significant difference in cirrhosis progression between different HBV-DNA groups at baseline (P = 0.531). Kaplan-Meier analysis showed higher HBV-DNA level at endpoint had increasing risk of cirrhosis (P = 0.019). The results of Cox model indicated that HBV-DNA levels at endpoint, stage of fibrosis, negative hepatitis B e antigen, and γ-glutamyl transpeptidase at baseline were independent risk factors of cirrhosis. The relative risk ratios were 1.898, 1.918, 8.976, and 1.006, respectively. Progression to cirrhosis in chronic hepatitis B patients is correlated with HBV-DNA levels during follow-up.
Keywords hepatitis B, chronic      viral load      liver cirrhosis      
Issue Date: 05 September 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0054-1     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I3/271
Lee W M. Hepatitis B virus infection. N Engl JMed, 1997, 337(24): 1733–1745

doi: 10.1056/NEJM199712113372406
Huo T, Wu J C, Hwang S J, Lai C R, Lee P C, Tsay S H, Chang F Y, Lee S D. Factors predictive of liver cirrhosis in patients withchronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol, 2000, 12(6): 687–693

doi: 10.1097/00042737-200012060-00019
Yuen M F, Yuan H J, Wong D K, Yuen J C, Wong W M, Chan A O, Wong B C, Lai K C, Lai C L. Prognosticdeterminants for chronic hepatitis B in Asians: therapeutic implications. Gut, 2005, 54(11): 1610–1614

doi: 10.1136/gut.2005.065136
Park B K, Park Y N, Ahn S H, Lee K S, Chon C Y, Moon Y M, Park C, Han K H. Long-term outcome of chronic hepatitis B based on histologicalgrade and stage. J Gastroenterol Hepatol,2007, 22(3): 383–388

doi: 10.1111/j.1440-1746.2007.04857.x
Iloeje U H, Yang H I, Su J, Jen C L, You S L, Chen C J. Predicting cirrhosis risk based on the level of circulating hepatitisB viral load. Gastroenterology, 2006, 130(3): 678–686

doi: 10.1053/j.gastro.2005.11.016
Su C W, Huang Y H, Huo T I, Shih H H, Sheen I J, Chen S W, Lee P C, Lee S D, Wu J C. Genotypesand viremia of hepatitis B and D viruses are associated with outcomesof chronic hepatitis D patients. Gastroenterology, 2006, 130(6): 1625–1635

doi: 10.1053/j.gastro.2006.01.035
Yuen M F, Ng I O, Fan S T, Yuan H J, Wong D K, Yuen J C, Sum S S, Chan A O, Lai C L. Significanceof HBV DNA levels in liver histology of HBeAg and Anti-HBe positivepatients with chronic hepatitis B. Am JGastroenterol, 2004, 99(10): 2032–2037

doi: 10.1111/j.1572-0241.2004.40440.x
Mommeja-Marin H, Mondou E, Blum M R, Rousseau F. SerumHBV DNA as a marker of efficacy during therapy for chronic HBV infection:Analysis and review of the literature. Hepatology, 2003, 37(6): 1309–1319

doi: 10.1053/jhep.2003.50208
Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinomain patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol, 2004, 19(6): 670–675

doi: 10.1111/j.1440-1746.2004.03360.x
Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, Suehiro M, Kawanaka M, Togawa K, Yamada G. Influence of viral load andgenotype in the progression of Hepatitis B-associated liver cirrhosisto hepatocellular carcinoma. Liver Int, 2005, 25(2): 220–225

doi: 10.1111/j.1478-3231.2005.01077.x
Tang B, Kruger W D, Chen G, Shen F, Lin W Y, Mboup S, London W T, Evans A A. Hepatitis B viremia is associated with increased riskof hepatocellular carcinoma in chronic carriers. J Med Virol, 2004, 72(1): 35–40

doi: 10.1002/jmv.10559
Fung J, Yuen M F, Yuen J C, Wong D K, Lai C L. Low serum HBV DNA levels and developmentof hepatocellular carcinoma in patients with chronic hepatitis B:a case-control study. Aliment PharmacolTher, 2007, 26(3): 377–382
Chen C J, Yang H I, Su J, Jen C L, You S L, Lu S N, Huang G T, Iloeje U H. Risk of hepatocellular carcinoma across a biologicalgradient of serum hepatitis B virus DNA level. JAMA, 2006, 295(1): 65–73

doi: 10.1001/jama.295.1.65
Perrillo R. HepatitisB virus replication x time equals trouble. Gastroenterology, 2006, 130(3): 989–991

doi: 10.1053/j.gastro.2006.01.070
Chen C J, Iloeje U H, Yang H I. Long-term outcomes in hepatitis B: The REVEAL-HBV Study. Clin Liver Dis, 2007, 11(4): 797–816

doi: 10.1016/j.cld.2007.08.005
Lok A S, McMahon B J. Chronic hepatitis B. Hepatology, 2007, 45(2): 507–539

doi: 10.1002/hep.21513
Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol, 1991, 13(3): 372–374

doi: 10.1016/0168-8278(91)90084-O
Weisberg I S, Brown Jr R S, Sigal S H. Hepatitis B and end-stage liver disease. Clin Liver Dis, 2007, 11(4): 893–916

doi: 10.1016/j.cld.2007.08.009
Schuppan D, Afdhal N H. Liver cirrhosis. Lancet, 2008, 371(9615): 838–851

doi: 10.1016/S0140-6736(08)60383-9
Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F, Nasiri J, Nobakht H, Forouzanfar M H, Abedian S, Tavangar S M, Mohamadkhani A, Ghoujeghi F, Estakhri A, Nouri N, Farzadi Z, Najjari A, Malekzadeh R. Noninvasive markers of liverfibrosis and inflammation in chronic hepatitis B-virus related liverdisease. Am J Gastroenterol, 2006, 101(11): 2537–2545
D'Onofrio M, Martone E, Brunelli S, Faccioli N, Zamboni G, Zagni I, Fattovich G, Pozzi Mucelli R. Accuracy of ultrasound inthe detection of liver fibrosis in chronic viral hepatitis. Radiol Med, 2005, 110(4): 341–348
Shen L, Li J Q, Zeng M D, Lu L G, Fan S T, Bao H. Correlationbetween ultrasonographic and pathologic diagnosis of liver fibrosisdue to chronic virus hepatitis. World JGastroenterol. 2006, 12(8): 1292–1295
Hung C H, Lu S N, Wang J H, Lee C M, Chen T M, Tung H D, Chen C H, Huang W S, Changchien C S. Correlation between ultrasonographic and pathologic diagnoses ofhepatitis B and C virus-related cirrhosis. J Gastroenterol, 2003, 38(2): 153–157

doi: 10.1007/s005350300025
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasison disease progression and prognostic factors. J Hepatol, 2008, 48(2): 335–352

doi: 10.1016/j.jhep.2007.11.011
Hadziyannis S J, Papatheodoridis GV. Hepatitis Be antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis, 2006, 26(2): 130–141

doi: 10.1055/s-2006-939751
Ma H, Guo F, Wei L, Sun Y, Wang H. The prospective study of the clinicalfeatures and outcome of HBeAg-negative and HBeAg-positive cirrhosisin patients with chronic type B hepatitis. Zhonghua Yi Xue Za Zhi, 2007, 87(26): 1832–1835 (in Chinese)
Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesisin patients with chronic viral hepatitis: a prospective observationof 2215 patients. J Hepatol, 1998, 28(6): 930–938

doi: 10.1016/S0168-8278(98)80339-5
Brunetto M R, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin J M, Bonino F. Outcomeof anti-HBe positive chronic hepatitis B in alpha-interferon treatedand untreated patients: a long term cohort study. J Hepatol, 2002, 36(2): 263–270

doi: 10.1016/S0168-8278(01)00266-5
Dienstag J L, Goldin R D, Heathcote E J, Hann H W, Woessner M, Stephenson S L, Gardner S, Gray D F, Schiff E R. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124(1): 105–117

doi: 10.1053/gast.2003.50013
Liaw Y F, Sung J J, Chow W C, Farrell G, Lee C Z, Yuen H, Tanwandee T, Tao Q M, Shue K, Keene O N, Dixon J S, Gray D F, Sabbat J. Lamivudine for patients withchronic hepatitis B and advanced liver disease. N Engl J Med, 2004, 351(15): 1521–1531

doi: 10.1056/NEJMoa033364
[1] Ling YANG, Rui ZHU, Qingjing ZHU, Dan DAN, Jin YE, Keshu XU, Xiaohua HOU. Influence of β-elemene on the secretion of angiotensin II and expression of AT1R in hepatic stellate cells[J]. Front Med Chin, 2009, 3(1): 36-40.
[2] CHU Deyong, LI Conglei, SHEN Jilong, WU Qiang. Paeoniflorin prevents hepatic fibrosis of by inhibiting TGF-β1 production from macrophages in mice[J]. Front. Med., 2008, 2(2): 154-165.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed